Rocha GR et al. |
Effect of tt-farnesol and myricetin on in vitro biofilm formed by Streptococcus mutans and Candida albicans. |
2018 |
BMC Complement Altern Med |
pmid:29444673
|
Jeon JG et al. |
Influences of naturally occurring agents in combination with fluoride on gene expression and structural organization of Streptococcus mutans in biofilms. |
2009 |
BMC Microbiol. |
pmid:19863808
|
Cerca N et al. |
Confocal laser scanning microscopy analysis of S. epidermidis biofilms exposed to farnesol, vancomycin and rifampicin. |
2012 |
BMC Res Notes |
pmid:22591918
|
Langman MJ et al. |
Treatment of chronic gastric ulcer with carbenoxolone and gefarnate: a comparative trial. |
1973 |
Br Med J |
pmid:4577839
|
Alves FR et al. |
Antibiofilm and antibacterial activities of farnesol and xylitol as potential endodontic irrigants. |
2013 |
Braz Dent J |
pmid:23969910
|
Alves FR et al. |
Biofilm biomass disruption by natural substances with potential for endodontic use. |
2013 Jan-Feb |
Braz Oral Res |
pmid:23306623
|
Journe F et al. |
Farnesol, a mevalonate pathway intermediate, stimulates MCF-7 breast cancer cell growth through farnesoid-X-receptor-mediated estrogen receptor activation. |
2008 |
Breast Cancer Res. Treat. |
pmid:17333335
|
Still K et al. |
Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro. |
2003 |
Calcif. Tissue Int. |
pmid:12457261
|
Braun PC |
The effect of farnesol on amino acid incorporation by a wild-type and cell-wall variant strain of Candida albicans. |
2005 |
Can. J. Microbiol. |
pmid:16234870
|
Tsimberidou AM et al. |
Phase 1 first-in-human clinical study of S-trans,trans-farnesylthiosalicylic acid (salirasib) in patients with solid tumors. |
2010 |
Cancer Chemother. Pharmacol. |
pmid:19484470
|
Haklai R et al. |
Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice. |
2008 |
Cancer Chemother. Pharmacol. |
pmid:17909812
|
Au-Yeung KK et al. |
Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPARgamma. |
2008 |
Cancer Invest. |
pmid:18608213
|
Joo JH and Jetten AM |
Molecular mechanisms involved in farnesol-induced apoptosis. |
2010 |
Cancer Lett. |
pmid:19520495
|
Mo H et al. |
Farnesyl anthranilate suppresses the growth, in vitro and in vivo, of murine B16 melanomas. |
2000 |
Cancer Lett. |
pmid:10936674
|
Yazlovitskaya EM and Melnykovych G |
Selective farnesol toxicity and translocation of protein kinase C in neoplastic HeLa-S3K and non-neoplastic CF-3 cells. |
1995 |
Cancer Lett. |
pmid:7874691
|
Adany I et al. |
Differences in sensitivity to farnesol toxicity between neoplastically- and non-neoplastically-derived cells in culture. |
1994 |
Cancer Lett. |
pmid:8019976
|
McAnally JA et al. |
Farnesyl-O-acetylhydroquinone and geranyl-O-acetylhydroquinone suppress the proliferation of murine B16 melanoma cells, human prostate and colon adenocarcinoma cells, human lung carcinoma cells, and human leukemia cells. |
2003 |
Cancer Lett. |
pmid:14643448
|
Blum R et al. |
Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S-farnesylthiosalicylic acid). |
2007 |
Cancer Res. |
pmid:17409441
|
Joo JH et al. |
Farnesol-induced apoptosis in human lung carcinoma cells is coupled to the endoplasmic reticulum stress response. |
2007 |
Cancer Res. |
pmid:17699800
|
Blum R et al. |
Ras inhibition in glioblastoma down-regulates hypoxia-inducible factor-1alpha, causing glycolysis shutdown and cell death. |
2005 |
Cancer Res. |
pmid:15705901
|